VIDEO: Emerging treatments in DME

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Something really exciting that we've seen for diabetic macular edema is the commercialization and widespread use of faricimab for diabetic eye disease. That's exciting because it does have a second pathway, the second target, the angiopoietin pathway that many of us have learned a lot about in the last year and longer if we've been involved in the clinical development of faricimab. And I think that the results that we've seen from that have been very impressive. We have over 300,000 doses commercially, and we've seen good efficacy without significant concern for safety. Additionally, we have high-dose aflibercept coming right behind it, likely to be reviewed by the FDA later this year. And I'm optimistic that we're going to have that as an option for diabetic patients too, and as all of our viewers know, we've been using aflibercept effectively for over a decade. And it'll be nice to see if this increased concentration improves our outcomes even further with that biologic.